Matrix metalloproteinase MMP-8, TIMP-1 and MMP-8/TIMP-1 ratio in plasma in methicillin-sensitive Staphylococcus aureus bacteremia.
Aged
Anti-Bacterial Agents
/ therapeutic use
Area Under Curve
Bacteremia
/ diagnosis
Biomarkers
/ blood
Blood Culture
Female
Gene Expression
Humans
Male
Matrix Metalloproteinase 8
/ blood
Middle Aged
Prospective Studies
ROC Curve
Sepsis
/ diagnosis
Severity of Illness Index
Staphylococcal Infections
/ diagnosis
Staphylococcus aureus
/ growth & development
Survival Analysis
Tissue Inhibitor of Metalloproteinase-1
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
11
2020
accepted:
10
05
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of metalloproteinases-1 (TIMP-1) have been shown to predict prognosis in sepsis. However, MMP-8 and TIMP-1 in Staphylococcus aureus bacteremia (SAB) lacks evaluation and their role in the pathogenesis of SAB is unclear. MMP-8 and TIMP-1 and MMP-8/TIMP-1 molar ratio were determined at days 3, 5 and 28 from positive blood cultures in patients with methicillin-sensitive SAB and the connection to disease severity and early mortality was determined. Altogether 395 SAB patients were included. Patients with severe sepsis or infection focus presented higher MMP-8 levels at day 3 and 5 (p<0.01). Higher day 3 and 5 MMP-8 levels were associated to mortality at day 14 and 28 (p<0.01) and day 90 (p<0.05). Day 3 MMP-8 cut-off value of 203 ng/ml predicted death within 14 days with an area under the curve (AUC) of 0.70 (95% CI 0.57-0.82) (p<0.01). Day 5 MMP-8 cut-off value of 239 ng/ml predicted death within 14 days with an AUC of 0.76 (95% CI 0.65-0.87) (p<0.001). The results for MMP-8/TIMP-1 resembled that of MMP-8. TIMP-1 had no prognostic impact. In Cox regression analysis day 3 or 5 MMP-8 or day 3 MMP-8/TIMP-1 had no prognostic impact whereas day 5 MMP-8/TIMP-1 predicted mortality within 14 days (HR, 4.71; CI, 95% 1.67-13.3; p<0.01). MMP-8 and MMP-8/TIMP-1 ratio were high 3-5 days after MS-SAB diagnosis in patients with an infection focus, severe sepsis or mortality within 14 days suggesting that matrix metalloproteinase activation might play a role in severe SAB.
Sections du résumé
BACKGROUND
Matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of metalloproteinases-1 (TIMP-1) have been shown to predict prognosis in sepsis. However, MMP-8 and TIMP-1 in Staphylococcus aureus bacteremia (SAB) lacks evaluation and their role in the pathogenesis of SAB is unclear.
METHODS
MMP-8 and TIMP-1 and MMP-8/TIMP-1 molar ratio were determined at days 3, 5 and 28 from positive blood cultures in patients with methicillin-sensitive SAB and the connection to disease severity and early mortality was determined.
RESULTS
Altogether 395 SAB patients were included. Patients with severe sepsis or infection focus presented higher MMP-8 levels at day 3 and 5 (p<0.01). Higher day 3 and 5 MMP-8 levels were associated to mortality at day 14 and 28 (p<0.01) and day 90 (p<0.05). Day 3 MMP-8 cut-off value of 203 ng/ml predicted death within 14 days with an area under the curve (AUC) of 0.70 (95% CI 0.57-0.82) (p<0.01). Day 5 MMP-8 cut-off value of 239 ng/ml predicted death within 14 days with an AUC of 0.76 (95% CI 0.65-0.87) (p<0.001). The results for MMP-8/TIMP-1 resembled that of MMP-8. TIMP-1 had no prognostic impact. In Cox regression analysis day 3 or 5 MMP-8 or day 3 MMP-8/TIMP-1 had no prognostic impact whereas day 5 MMP-8/TIMP-1 predicted mortality within 14 days (HR, 4.71; CI, 95% 1.67-13.3; p<0.01).
CONCLUSION
MMP-8 and MMP-8/TIMP-1 ratio were high 3-5 days after MS-SAB diagnosis in patients with an infection focus, severe sepsis or mortality within 14 days suggesting that matrix metalloproteinase activation might play a role in severe SAB.
Identifiants
pubmed: 34043679
doi: 10.1371/journal.pone.0252046
pii: PONE-D-20-34377
pmc: PMC8158883
doi:
Substances chimiques
Anti-Bacterial Agents
0
Biomarkers
0
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
MMP8 protein, human
EC 3.4.24.34
Matrix Metalloproteinase 8
EC 3.4.24.34
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0252046Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2017 Feb 13;12(2):e0171191
pubmed: 28192449
Acta Anaesthesiol Scand. 2015 Feb;59(2):176-84
pubmed: 25329743
Matrix Biol. 2015 May-Jul;44-46:247-54
pubmed: 25805621
Wien Klin Wochenschr. 2021 Feb;133(3-4):86-95
pubmed: 31932967
Front Immunol. 2018 Apr 06;9:691
pubmed: 29681903
Crit Care. 2009;13(5):R158
pubmed: 19799791
PLoS One. 2014 Apr 11;9(4):e94318
pubmed: 24727739
Shock. 2004 Oct;22(4):376-9
pubmed: 15377895
Shock. 2009 Feb;31(2):146-50
pubmed: 18636041
Ann N Y Acad Sci. 1994 Sep 6;732:424-6
pubmed: 7978828
J Intern Med. 2006 Feb;259(2):179-90
pubmed: 16420547
Shock. 2005 Sep;24(3):214-8
pubmed: 16135959
Clin Infect Dis. 2003 Jan 1;36(1):53-9
pubmed: 12491202
Crit Care. 2010;14(2):R49
pubmed: 20356362
Shock. 2007 Feb;27(2):145-50
pubmed: 17224788
Scand J Infect Dis. 2005;37(8):572-578
pubmed: 16138425
J Intensive Care Med. 2020 Jan;35(1):95-103
pubmed: 28931365
Clin Infect Dis. 2003 Jun 1;36(11):1418-23
pubmed: 12766837
Int J Infect Dis. 2011 Jan;15(1):e58-62
pubmed: 21111647
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
J Infect Dis. 1982 Aug;146(2):227-34
pubmed: 7108273
J Hosp Infect. 2011 Jun;78(2):102-7
pubmed: 21511366
Pharmacol Res. 2011 Dec;64(6):590-4
pubmed: 21742038
Ann Med. 2009;41(3):208-15
pubmed: 18979291
Clin Microbiol Infect. 2015 Aug;21(8):779-85
pubmed: 26033668
J Biol Chem. 1997 Dec 12;272(50):31504-9
pubmed: 9395486
Clin Infect Dis. 2000 Apr;30(4):633-8
pubmed: 10770721
Inflamm Res. 2014 May;63(5):329-34
pubmed: 24378958
Br J Surg. 1997 Feb;84(2):160-6
pubmed: 9052425
Biochem Soc Symp. 2003;(70):201-12
pubmed: 14587293
Anesth Analg. 2014 Apr;118(4):790-8
pubmed: 24651234
Am J Med. 2010 Jul;123(7):631-7
pubmed: 20493464
Infect Immun. 2000 Jul;68(7):3965-70
pubmed: 10858210
Am J Med Sci. 1998 Dec;316(6):355-60
pubmed: 9856688
Crit Care. 2013 May 25;17(3):R94
pubmed: 23706069
Scand J Infect Dis. 2006;38(10):867-72
pubmed: 17008230
Clin Microbiol Infect. 2016 Nov;22(11):948.e1-948.e7
pubmed: 27515395
Clin Infect Dis. 2009 Oct 1;49(7):997-1005
pubmed: 19719417
Eur J Clin Invest. 2016 Sep;46(9):757-65
pubmed: 27296149
Ann Med. 2006;38(5):306-21
pubmed: 16938801
Clin Exp Immunol. 2005 Oct;142(1):12-20
pubmed: 16178851
Diagn Microbiol Infect Dis. 1999 Apr;33(4):283-97
pubmed: 10212756
J Infect. 2009 Oct;59(4):232-9
pubmed: 19654021
PLoS One. 2015 Apr 13;10(4):e0122824
pubmed: 25874546
FEMS Immunol Med Microbiol. 1993 Oct;7(3):281-7
pubmed: 8275059
Ann Intern Med. 2004 Jan 6;140(1):26-32
pubmed: 14706969
Trends Cardiovasc Med. 2011 May;21(4):112-8
pubmed: 22681966